Immunization with r-<i>Lactococcus lactis</i>expressing outer membrane protein A of<i>Shigella dysenteriae</i>type-1: evaluation of oral and intranasal route of administration

Yagnik, Bhrugu; Sharma, Drashya; Padh, Harish; Desai, Priti

doi:10.1111/jam.13353

Cited by 15 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We had previously reported the immunogenic potential of orally and nasally administered r-L. lactis expressing OmpA (LacVax Ò OmpA) of S. dysenteriae type-1 (SD-1) in BALB/c mice [10]. The antibody titer of orally vaccinated animals in the previous study was 1:50, whereas, in the present study, we could achieve 1:1000 anti-OmpA titer by increasing the vaccine dose by 10 fold.…”

Section: Humoral Response Following Oral Immunization With Lacvax ò Ompacontrasting

confidence: 47%

“…Moreover, the immunostimulatory properties of L. lactis act as an adjuvant, encouraging its use as an antigen delivery vehicle. We have previously reported that r-L. lactis expressing a well conserved, immunodominant Shigella antigen, OmpA, induced antigen specific systemic and mucosal immune responses when given orally to BALB/c mice [8,10].…”

Section: Discussionmentioning

confidence: 99%

“…OmpA specific serum IgG and fecal IgA antibodies were detected by Enzyme Linked Immunosorbent Assay (ELISA) as described by Yagnik et al [10]. The ELISA results are expressed as the Optical Density (OD) values measured at 405 nm with a Multiskan GO microplate spectrophotometer (Thermo Scientific, USA) for dilutions of 1:1000 for serum and 1:2 for fecal extracts.…”

Section: Ompa Specific Serum Igg and Fecal Iga Antibodiesmentioning

confidence: 99%

“…In this regard, our group has explored food grade Lactococcus lactis as an antigen and DNA vaccine delivery vehicle against enteric pathogens such as Shigella [8][9][10][11]. We have developed non-invasive and invasive r-L. lactis harbouring DNA vaccine reporter plasmid and evaluated DNA delivery potential of these strains in vitro as well as in vivo [9,11].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model

Yagnik

Sharma

Padh

et al. 2019

Vaccine

View full text Add to dashboard Cite

a b s t r a c tShigellosis is an acute invasive disease of the lower intestine, which afflicts millions of people worldwide with an estimated one million fatalities per annum. Despite of extensive research during the last two decades, a vaccine against multi-drug resistant Shigella is not yet available in the market. To provide a safe, effective and broad-spectrum vaccine against Shigella, we explored food grade bacteria Lactococcus lactis (L. lactis) for the delivery of conserved antigenic protein; Outer membrane protein A (OmpA) to the mucosal sites for effective elicitation of systemic and mucosal immunity. We have previously confirmed the immunogenic potential of recombinant L. lactis expressing OmpA (LacVax Ò OmpA) in BALB/c mice. In the present study, we have characterized the humoral and cellular immune profile of LacVax Ò OmpA and assessed its protective efficacy using a newly developed human like murine shigellosis model. The significant increase in OmpA specific serum IgG, fecal sIgA and a Th1 dominant immune response (indicated by high INF-c/IL-4 ratio) in LacVax Ò OmpA immunized mice revealed successful activation of humoral and cellular immunity. The LacVax Ò OmpA immunized animals were also protected from human-like shigellosis when challenged with S. flexneri 2a ATCC 12022. The antigen specific serum IgG, fecal sIgA, INF-c and IL-10 levels were found to be the significant correlates of protection. Collectively these results suggest that the LacVax Ò OmpA is a promising prophylactic candidate against shigellosis. However, the protective efficacy of LacVax Ò OmpA in the higher animals would further strengthen its future application in humans.

show abstract

Section: Humoral Response Following Oral Immunization With Lacvax ò Ompacontrasting

confidence: 47%

Section: Discussionmentioning

confidence: 99%

Section: Ompa Specific Serum Igg and Fecal Iga Antibodiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model

Yagnik

Sharma

Padh

et al. 2019

Vaccine

View full text Add to dashboard Cite

show abstract

“…route. 59 In another study, Oliveira et al. delivered a plasmid DNA vaccine expressing the Rho1 GTP protein of Schistosoma mansoni with chitosan nanoparticles.…”

Section: Oral Vaccination Preclinical Applicationsmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effective in humans there are some issues that should be considered, such as the adjuvant, the route of vaccination, and the antigen-carrier system. While almost all licensed vaccines are injected such that inoculation is by far the most commonly used method, injection has several potential disadvantages, including pain, cross contamination, needlestick injury, under- or overdosing, and increased cost. It is also problematic for patients from rural areas of developing countries, who must travel to a hospital for vaccine administration. Noninvasive immunizations, including oral, intranasal, and transcutaneous administration of vaccines, can reduce or eliminate pain, reduce the cost of vaccinations, and increase their safety. Several preclinical and clinical studies as well as experience with licensed vaccines have demonstrated that noninvasive vaccine immunization activates cellular and humoral immunity, which protect against pathogen infections. Here we review the development of noninvasive immunization with vaccines based on live attenuated virus, recombinant adenovirus, inactivated virus, viral subunits, virus-like particles, DNA, RNA, and antigen expression in rice in preclinical and clinical studies. We predict that noninvasive vaccine administration will be more widely applied in the clinic in the near future.

show abstract

Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides

Plavec

Berlec

2019

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Immunization with r-Lactococcus lactisexpressing outer membrane protein A ofShigella dysenteriaetype-1: evaluation of oral and intranasal route of administration

Cited by 15 publications

References 39 publications

Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model

Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model

Noninvasive vaccination against infectious diseases

Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides

Contact Info

Product

Resources

About